Its Class A common stock and warrants are listed on the Nasdaq under the symbol "HCCC" and "HCCCW," respectively. About Alpha Tau Medical Ltd.Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. - Alpha Tau's proprietary Alpha DaRT is designed to deliver uniquely potent alpha radiation to destroy solid tumors with localized precision, sparing surrounding healthy tissue, thereby maintaining cancer patients' quality of life. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University. Alpha Tau Medical and Healthcare Capital Corp. Cantor Fitzgerald acted as a capital markets advisor to HCCC. Cision Distribution 888-776-0942 Forward-Looking StatementsThis press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Citigroup acted as lead financial advisor to Alpha Tau. Leverage your professional network, and get hired. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking.
| Source:
Potential candidates will appreciate our experienced operator mindset, industry, and global connections that can facilitate strategic partnerships and expansion opportunities as well as ease their transition to public ownership. Alpha Tau Medical and Healthcare Capital Corp. - The transaction represents an impliedpro forma equity value of approximately $1 billion and is expected to provide up to $367 million in gross proceeds, includingup to $275 million of cash held in the trust account of Healthcare Capital Corp. (Nasdaq: HCCC) and a $92 million PIPE.
PDF Company Overview - Healthcare Capital Corp Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau Is Expected to Commence Trading on Nasdaq Under the Ticker "DRTS" on March 8, 2022 JERUSALEM and WILMINGTON, Del., March 7, 2022 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, and Healthcare Capital Corp. (Nasdaq: HCCC) ("HCCC"), a special purpose acquisition company, announced today the successful closing of the .
Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain.
Alpha Tau has developed a robust clinical trial strategy with leading global centers, including its flagship US multi-center feasibility study currently ongoing, led at Memorial Sloan Kettering Cancer Center in New York, which recently enrolled its first patient. Additional information about the proposed business combination, including a copy of the definitive agreement and investor presentation, will be provided in a Current Report on Form 8-K to be filed by HCC with the Securities and Exchange Commission and available at www.sec.gov. The Special Meeting will be held as a virtual meeting via live audio webcast at https://www.cstproxy.com/healthcarecapitalcorp/2022. Alpha Tau Medical Ltd.Amnon Gat, COO[emailprotected], Healthcare Capital Corp.William Johns, CEO[emailprotected], SOURCE Alpha Tau Medical; Healthcare Capital Corp, www.netroadshow.com/nrs/home/#!/?show=d422ce03. Through completion of the Business Combination, Alpha Tau has raised approximately $90 million in gross cash proceeds. All forward-looking statements are based upon the Alpha Tau's current expectations and various assumptions.
Notice of the Special Meeting was mailed on or about January 18, 2022 to stockholders of record as of the Record Date. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau's ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau's limited operating history; (iii) Alpha Tau's incurrence of significant losses to date; (iv) Alpha Tau's need for additional funding and ability to raise capital when needed; (v) Alpha Tau's limited experience in medical device discovery and development; (vi) Alpha Tau's dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau's clinical studies to predict final study results; (viii) failure of Alpha Tau's early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau's ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau's Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau's exposure to patent infringement lawsuits; (xii) Alpha Tau's ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq's listing standards following the consummation of the Business Combination; (xiv) the outcome of any legal proceedings that may be instituted against Alpha Tau or others following the consummation of the Business Combination and any definitive agreements with respect thereto(xv) the risk that the Business Combination disrupts current plans and operations of Alpha Tau as a result of the consummation of the transaction described herein; (xvi) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (xvii) costs related to the Business Combination and being a public company; (xviii) changes in applicable laws or regulations; (xix) impacts from the COVID-19 pandemic; and the other important factors discussed under the caption "Risk Factors" in Alpha Tau's final proxy statement/prospectus relating to the Business Combination filed with the SEC on January 13, 2022, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. brachytherapy as well as the benefits of alpha therapy.brachytherapy as well as the benefits of alpha therapyin terms of efficacy and safety. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Copyright 2023 Surperformance.
Any such forward-looking statements represent management's estimates as of the date of this press release.
SEC.gov In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking.
The transaction, and the various proposals giving effect thereto, were approved by the requisite vote of HCCC stockholders at a special meeting of HCCC's stockholders held on February 18, 2022. HCCC Healthcare Capital Corporation Alpha Tau Announces Completion of Enrollment in First US Clinical Trial of Alpha DaRT and Achievement of First Primary Objective. In connection with the proposed transaction with HCCC, Alpha Tau has filed a Registration Statement on Form F-4, which includes a preliminary proxy statement/prospectus of HCCC, which was declared effective on January 12, 2022. Selected Questions and Answers About Stockholder Meeting of Healthcare Capital Corp. to Approve Its Business Combination with Alpha Tau Medical LTD. When used herein, words including anticipate, being, will, plan, may, continue, and similar expressions are intended to identify forward-looking statements. Our mission is to identify them, provide the capital, expertise and guidance they may need and successfully transition them to public ownership. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University. , . Investors and security holders may obtain more detailed information regarding the names and interests in the proposed transaction of HCCCs directors and officers HCCCs and Alpha Taus filings with the SEC, including the Registration Statement. A link to a presentation by management of Alpha Tau and HCC discussing the business and the proposed transaction can be found at www.netroadshow.com/nrs/home/#!/?show=d422ce03. Chuck Padala. "As we redouble our efforts to bring our Alpha DaRT technology to patients around the world, we are confident that this significant inflow of funds will carry us through a significant number of meaningful milestones. Since the alpha-emitting atoms diffuse only a short distance in tissue, Alpha DaRT mainly damages the tumor, while sparing the healthy tissue around it. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain.
Citigroup acted as lead financial advisor to Alpha Tau. Announces Adjournment of Special Meeting of Stockholders.
Alpha Tau Is Expected to Commence Trading on Nasdaq Under the Ticker "DRTS" on March 8, 2022. Citigroup acted as lead financial advisor to Alpha Tau. Type a symbol or company name. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. JERUSALEM and WILMINGTON, Del., March 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, and. Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. Through completion of the Business Combination, Alpha Tau has raised approximately $90 million in gross cash proceeds. The transaction, and the various proposals giving effect thereto, were approved by the requisite vote of HCCC stockholders at a special meeting of HCCC's stockholders held on February 18, 2022.
Healthcare Capital Corp. and Alpha Tau Medical Ltd. - GlobeNewswire The transaction, and the various proposals giving effect thereto, were approved by the requisite vote of HCCC stockholders at a special meeting of HCCC's stockholders held on February 18, 2022. Any such forward-looking statements represent management's estimates as of the date of this press release. Our unique mix makes us different from other SPACs.
Alpha Tau Announces Completion of Enrollment of Japanese Pivotal Alpha Tau may not realize its expectations, and its beliefs may not prove correct. "The completion of this transaction will allow the company to realize its vision and implement the clinical development plans and construction of our manufacturing plants around the world, in order to bring hope to millions of patients around the world. Our team includes medical business operators, entrepreneurs, and financial experts. The study will be led by Gabriel Sawakuchi, Ph.D., Associate Professor of Radiation Physics, and Simona Shaitelman, M.D., Associate Professor of Radiation Oncology at MD Anderson, together with Alpha Tau's translational research and physics teams. The firm has an $18 price target (81% upside based on Friday's close). Following the closing of the business combination, Alpha Tau is expected to be listed on the Nasdaq. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement/prospectus regarding the proposed transaction. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. Share this article - Alpha Tau's proprietary Alpha DaRT . - The $92 million fully-committed PIPE is anchored by a combination of Healthcare-focused financial and strategic investors including Yozma Investment Co. (part of Yozma Group Korea), Grand Decade Developments (an affiliate of China Grand Pharmaceutical and Healthcare Holdings), as well as other leading technology investors including OurCrowd, Regah Ventures and the co-founders of Apax Partners, Alan Patricof and Sir Ronald Cohen. Create your Watchlist to save your favorite quotes on Nasdaq.com.
Investors and security holders may obtain more detailed information regarding the names and interests in the proposed transaction of HCCC's directors and officers HCCC's and Alpha Tau's filings with the SEC, including the Registration Statement. "We look forward to delivering continued clinical momentumand hope for patients as we evolve into a public company. "My background as a medical and radiation oncologist helped me immediately appreciate the potential of Alpha Tau's therapy in providing a solution for a potentially significant number of patients, including those with untreatable or difficult to treat tumors, whether alone or in combination with other therapies such as immunotherapies. Alpha DaRT(Diffusing Alpha-emitters Radiation Therapy) is an innovative technology that enables the highly potent and uniquely conformal alpha-irradiation of solid tumors. Alpha Tau and HCC and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from HCC's shareholders in connection with the proposed transaction. from 8 AM - 9 PM ET. Das smart lab Carinthia bietet Ihnen eine individuelle Auswahl an Kurse, Workshops & Seminaren fr Ihre Organisation und Bildungseinrichtung an. "We are excited to have reached the successful completion of the merger with HCCC, and appreciate the ongoing support of our existing investors and new joiners to the family, as well as all of the parties involved in bringing this momentous transaction to fruition," noted Alpha Tau CEO Uzi Sofer. By accepting this Presentation, you acknowledge and agree that all of the information .
These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. JERUSALEMand WILMINGTON, Del., July 8, 2021 /PRNewswire/ -- Alpha Tau Medical Limited ("Alpha Tau"), the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT, and Healthcare Capital Corp. ("HCC") (Nasdaq: HCCC), a special purpose acquisition company, today announced they have entered into a definitive business combination agreement (the "Business Combination"). Investors and security holders of HCCC are advised to read the definitive proxy statement filed by HCCC in connection with HCCCs solicitation of proxies for the Special Meeting because the proxy statement/prospectus contains important information about the proposed transaction and the parties to the proposed transaction.
Announce Stockholder Approval of the Business Combination, Healthcare Capital Corp. Type a symbol or company name. Contact: Amnon Gat+972-54-9746276amnong@alphatau.com, Logo - https://mma.prnewswire.com/media/733268/Alpha_Tau_Medical_Logo.jpg. This press release does not constitute (i) solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction or (ii) an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any security of HCC, Alpha Tau, or any of their respective affiliates, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. En vous inscrivant la newsletter, vous consentez la rception de contenus de notre part. The treatment is delivered by intratumoral insertion of radionuclide Radium-224, which leads to the release and diffusion of daughter radioisotopes that emit alpha particles.
Cetaphil Cleanser Cream,
Broadmoor All-weather Wicker Cushioned Patio Sofa,
Eaton Interview Process,
Hotel Giraffe By Library Hotel Collection,
What Is Idea Generation In New Product Development,
Spicer 5-3233x Cross Reference,
Gretsch Catalina 16'' Floor Tom,